Aquestive(US:AQST) Prnewswire·2026-03-10 13:00Core Viewpoint - A class action lawsuit has been filed against Aquestive Therapeutics, Inc. (AQST) due to allegations of misleading statements regarding the company's New Drug Application (NDA) for Anaphylm (Dibutepinephrine) sublingual film, which led to significant stock price declines for investors [1]. Summary by Relevant Sections Allegations - The complaint claims that Aquestive provided investors with positive statements while concealing material adverse facts about the NDA for Anaphylm, particularly regarding human factors in the use of the sublingual film [1]. - The company minimized the significance of packaging, use, administration, and labeling issues related to Anaphylm [1]. Stock Price Impact - Following the announcement of deficiencies identified by the FDA on January 9, 2026, the stock price of Aquestive fell from $6.21 per share on January 8, 2026, to $3.91 per share on January 9, 2026, marking a decline of over 37% in a single day [1]. Class Action Details - The class period for the lawsuit is defined as June 16, 2025, to January 8, 2026, with a deadline for shareholders to register for the class action set for May 4, 2026 [1]. - Shareholders who register will be enrolled in a portfolio monitoring software to receive updates on the case [1].